In vitro studies have shown Notch activity to be elevated in both bulk and BCSC populations in ER+ and HER2+ breast cancer cell lines, and this is enhanced upon treatment with therapies such as tamoxifen or trastuzumab, respectively. Here, ESR1 is linked to breast cancer.